Skip Nav Destination
![]()
You do not currently have access to this content.
GDF-15 Blockade Overcomes Resistance to Immune Checkpoint Inhibition
January 6, 2025
Main Findings: Visugromab, a GDF-15 blocking antibody, is tolerable and elicits clinical responses in combination with nivolumab.
Concept: GDF-15 may represent a mechanism of anti-PD-1 resistance that can be targeted to enhance antitumor immunity.
Impact: This phase I/IIa trial supports the safety and further clinical evaluation of this combination, particularly in NSCLC and urothelial cancer.
RSS Feeds